期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
AVANT公布CETi-1的阳性结果
1
作者 王吉云 《国外药讯》 2004年第3期32-33,共2页
关键词 AVANT免疫治疗公司 ceti-1 抗动脉粥样硬化疫苗 HDL-胆固醇 临床试验
在线阅读 下载PDF
Ce_xTi_(1-x)O_2 Mixed Oxides Supported CuO Catalyst for NO Reduction by CO 被引量:1
2
作者 楼莉萍 蒋晓原 +3 位作者 陈英旭 吕光烈 周仁贤 郑小明 《Journal of Rare Earths》 SCIE EI CAS CSCD 2003年第3期331-336,共6页
Ce x Ti 1- x O 2 mixed oxides of different mole ratios ( x =0, 0.1, 0.2~0.9, 1.0) were prepared by co precipitation of TiCl 4 with Ce(NO 3) 3 and then loaded with different amounts of CuO. The effe... Ce x Ti 1- x O 2 mixed oxides of different mole ratios ( x =0, 0.1, 0.2~0.9, 1.0) were prepared by co precipitation of TiCl 4 with Ce(NO 3) 3 and then loaded with different amounts of CuO. The effects of CuO on NO+CO reaction were investigated, and the structure and reductive properties of various CuO/Ce x Ti 1- x O 2 were characterized by the methodologies of BET, TPR and XRD. The results show that different Ce/Ti mole ratios and calcination temperatures induce changes of structure and reductive properties of the Ce x Ti 1- x O 2 mixed oxides. When x =0.1~0.5, amorphous CeTi 2O 6 phase mainly forms at 650 ℃ compared to the formation of CeTi 2O 6 which crystallizes at 800 ℃. When x >0.6, some TiO 2 enters the CeO 2 lattice and a CeO 2 TiO 2 solid solution is formed. The activity of 6%CuO/Ce x Ti 1- x O 2 calcined at 650 ℃ is largely affected by the x values, which is the highest when x =0.3, 0.4 and 0.9. The NO conversion reaches 70% at a reaction temperature of 150 ℃. By comparison, the x values have little effect on the activity of 6%CuO/Ce x Ti 1- x O 2 calcined at 800 ℃ . There are strong interactions between CuO and CeTi 2O 6, i.e., formation of the CeTi 2O 6 phase shifts the CuO reduction peak temperature from 380 to 200 ℃, and CuO, in turn, shifts the CeTi 2O 6 reduction peak temperature from 600 to 300 ℃. 展开更多
关键词 catalitic chemistry Ce x Ti 1- x O 2 mixed oxides CuO/Ce x Ti 1- x O 2 catalysts CeTi 2O 6 phase NO+CO reaction activity rare earths
在线阅读 下载PDF
胆固醇酯转移蛋白质抑制药在冠心病防治中的应用
3
作者 黄震华 《中国新药与临床杂志》 CAS CSCD 北大核心 2008年第2期132-135,共4页
胆固醇酯转移蛋白抑制药是一种新型的调脂药物,具有升高高密度脂蛋白,促进胆固醇转运等作用,在抗动脉粥样硬化和冠心病预防中发挥重要作用。
关键词 胆固醇酯转移蛋白质类 蛋白质合成抑制药 冠状动脉疾病 药物疗法 ceti-1 JTT-705 托塞匹布
暂未订购
上一页 1 下一页 到第
使用帮助 返回顶部